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Abstract
Aflatoxin B1 (AFB1) is the most potent known hepatocarcinogen. The signature 
p53 mutation (p53 249ser) that is found in AFB1-associated liver cancer suggests 
that AFB1 is a potent genotoxin. AFB1 is not genotoxic per se but is metabolically 
activated by cytochrome P450 enzymes that convert the promutagen into a highly 
reactive epoxide, which primarily reacts with the N7 group of guanine, forming 
8,9-dihydro-8-(N7-guanyl)-9-hydroxyaflatoxin B1 (AFB1-N7-dG). While this 
primary adduct is unstable, the subsequent trans-8,9-dihydro-8-(2,6-diamino- 
4-oxo-3,4-dihydropyrimid-5-yl-formamido)-9-hydroxy aflatoxin B1 (AFB1-Fapy)-
derived adducts are stable and are mutagenic. Studies have revealed that nucleotide 
excision repair (NER), base excision repair (BER), recombinational repair, and 
DNA replication bypass are all involved in conferring AFB1 resistance. To minimize 
the genotoxicity of AFB1, pathways function to detoxify the metabolically active 
intermediate, excise resulting DNA adducts, bypass unrepaired adducts, and repair 
secondary DNA breaks. How these repair pathways functionally cooperate to 
minimize AFB1-associated genetic instability phenotypes is not well understood. 
Insights can be gained from epidemiological research and model organisms. Gene 
profiling and next-generation sequencing are facilitating how pathways and tissue-
specific differences are induced. This review will encompass studies concerning 
human genetic susceptibility to AFB1 and pathways that repair and tolerate AFB1-
associated DNA damage.
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1. Introduction
The mycotoxin aflatoxin B1 (AFB1) is the most potent known liver carcinogen 
[1] and is also a lung [2] and esophageal carcinogen [3]. The International Agency 
for Research and Cancer (IARC) has classified AFB1 as a Group 1 human carcino-
gen [1]. AFB1 was discovered as the causative chemical agent in Turkey X disease, 
so named after a 1960 occurrence where 100,000 turkeys in Great Britain died 
after feeding on contaminated peanut meal imported from Brazil [4]. Its notoriety 
is underscored by its persistence in grain supplies, ground nuts and animal feed, 
which must be continually monitored [5]. Produced by aspergillus parasiticus 
and aspergillus flavis, the mycotoxin is a particular problem in subtropical areas 
of China, and in tropical areas of Southeast Asia and Africa [6, 7]. In temperate 
climates, such as in North America, high levels of AFB1 contamination have been 
found in corn and nuts, such as almonds and pistachios [8]. To minimize health 
risks in humans, the Food and Drug Administration (FDA) mandates that the 
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human food supply contain no more than 20 ppb AFB1 [5]. While human food 
supply is relatively protected in developed countries, outbreaks of acute mycotoxin 
contamination have been noted in third world countries and among animals, as 
recently as 2006 [5]. Although the incidence of acute aflatoxicosis is rare, it is esti-
mated that a large fraction of the population in the developing world are chronically 
exposed to AFB1 and thus at a higher risk for aflatoxin-associated cancer, especially 
liver cancer [6].
Liver cancer ranks third in all worldwide cancer mortalities [9–11] and ninth in 
cancer mortalities in the United States [12, 13]. 4–28% of cancer cases are related to 
AFB1 exposure [2]. Most liver cancer is characterized as hepatocellular carcinoma 
(HCC). HCC is highest where there is both a high rate of hepatitis B (HBV) [14, 15] and 
C virus (HCV) infection [15–17] and high levels of AFB1 contamination in the human 
food supply, especially in areas of Southeast Asia, China and Africa [6]. Interestingly, 
the incidence for liver cancer is higher in men than women, regardless of whether the 
cancer is associated with AFB1 exposure [18]. Because diagnosis is often late and there is 
no effective treatment for late-stage cancer, the five year survival rate is low in both men 
and women [12, 13]. The carcinogenic potency of AFB1 is correlated with AFB1 being 
a strong genotoxin, the signature p53 mutation, p53 249ser [19, 20], is found in 40–60% 
of all liver cancer derived from patients in heavily contaminated areas [2]. Animal 
studies have further strengthened the idea that AFB1 carcinogenicity is associated with 
its genotoxicity; AFB1-associated DNA adduct levels are directly proportional to the 
number of the animals stricken with liver cancer [21, 22].
Observations that HCC incidence is correlated to AFB1 exposure continues 
to motivate biomedical researchers to study the repair and toleration of AFB1-
associated DNA adducts, the cellular response to these DNA adducts, and 
associated factors that may enhance or mitigate the high mutagenicity of the 
DNA adducts in humans. This review will address (1) associated risk factors that 
enhance or synergize with AFB-associated DNA adducts that increase liver cancer 
incidence, (2) genetic instability phenotypes associated with AFB1-associated 
DNA adducts, and (3) repair mechanisms that have been elucidated in model 
organisms and conserved in humans, (4) cellular responses that enhance repair 
mechanisms, and (5) future directions in understanding the contributions of 
genes in AFB1-associated DNA repair. In particular, novel research that addresses 
epigenetic factors that can alter the repair of AFB1-associated genotoxic damage 
will be addressed.
2. Progression of HCC
Liver cancer progression is slow and the median age of onset is 60–65 years [11]; 
populations in areas that are at high risk for environmental and life-style factors 
are exceptions. For example, the incidence of liver cancer in the Qidong province 
of China peaks at 45 years [9, 11]. HCC generally develops as a consequence of liver 
injury, whether caused by chronic hepatitis or cirrhosis, which leads to chronic 
inflammation and deposition of connective tissue. Chronic hepatitis leads to 
upregulation of mitogenic pathways, partially through epigenetic mechanisms [23]. 
Monoclonal populations of dysplastic hepatocytes may exhibit telomere erosion and 
re-expression of telomerase to maintain viability. Eventual malignant cells accumu-
late irreversible genetic alterations [23]. As the transformed phenotype advances, 
the rate in the accumulation of genetic alterations increases [24]. The exact thresh-
old for the number of mutations or alterations present in liver cancer has not been 
established. Thus, the progression of liver cancer is associated and is accelerated 
with the accumulation of genetic mutations and altered gene expression patterns.
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2.1 Mutations that contribute to liver cancer
Understanding which HCC-associated genetic changes are associated with AFB1 
exposure requires a comparison of the genomic alterations that occur in sporadic 
HCC or HCC associated with other causes. For sporadic HCC, similar to solid 
tumors, there is both a multiplicity and heterogeneity in genetic alterations in HCC 
[23–25]. In general, these genetic alterations can be grouped into those that result 
in loss of function and those that result in gain of function. Genetic alterations that 
result in loss of function include dominant negative mutations and recessive muta-
tions, which are expressed after loss of heterozygosity (LOH).
Among sporadic tumors, both loss of heterozygosity (LOH) and mutations 
have been found in HCC tumors. Among 363 patients, The Cancer Genome Atlas 
Research Network [25], report that the most heavily mutated gene was TP53 (31%), 
encoding p53, followed by WNT pathway member CTNNB1 (27%), encoding 
β-catenin, and AXIN (8%), encoding a WNT signaling scaffolding protein, and 
chromatin remodeling genes (12%) [25]. In greater than 10% of HCC, mutations 
are found in CDH1, TP53, IGF2H, RB1, CDKN2A, PTEN, KLC, TP73, EXT, MLH1, 
THRB, THRA, E2F5, and CTNNB1 [23]. Whether these mutations occur early or 
late in the etiology of liver cancer is still not understood. While the p53 gene func-
tions in controlling the DNA damage response and apoptosis, the WNT pathway is 
important in controlling cell proliferation [23]. Many of the mutagenic events result 
from G to T transversions, unlike events found other tumors. The strong bias for G 
to T transversions suggests that these genetic alterations likely result from chemical 
DNA damaging agents, rather than spontaneous events, such as cytosine deamina-
tion [23]. While the heterogeneity in genetic mutations may reflect multiple mecha-
nisms for liver cell transformation, identifying alterations in HCC are informative 
in understanding the etiology and possible treatment of individual cancer cases. 
For example, β-catenin defective liver cancer may be easier to treat than liver cancer 
resulting from multiple mutations [23–25].
In addition to mutation and LOH events, gain-of-function genetic alterations 
may confer higher levels of oncogene expression and thereby accelerate carcino-
genesis [26–29]. Such alterations could include gene amplification events, such as 
c-N-methyl-N′-nitro-N-nitroso-guanidine HOS transforming gene (c-MET) and 
cyclin D (CCND1) [27]. Other gains of function mutations include mutations in 
the promoter for telomerases reverse transcriptase (TERT) promoter. TERT muta-
tions frequently were shown to be among the earliest and most prevalent neoplastic 
events in HCC [28, 30].
Both epidemiological and molecular pathology studies have facilitated the 
identification of which genetic alterations are likely to be associated AFB1 exposure. 
Mutated genes found in HCC from areas with high AFB1 exposure include p53 and 
β-catenin [30]. The p53 249ser mutation shows a strong correlation with HCC associ-
ated with AFB1 exposure, while is less frequent or absent in HCC from localities 
where there is little AFB1 exposure [19, 20]. For example, among have HCCs from 
southern Guangxi province of China, an area of high AFB1 exposure, the p53 249ser 
mutation was found in 36% of tumors [30]. CTNNB1 mutations and β-catenin 
protein accumulation in human hepatocellular carcinomas is also associated with 
high exposure to AFB1, although it is less clear whether these mutations directly 
result from AFB1-associated DNA adducts [30]. Whether these mutations must 
occur early or late in cancer progression is still unclear. One hypothesis is that initial 
mutations confer a higher level genetic instability that is aggravated by further 
exposure to genotoxic agents.
To determine whether mutations found in HCC confer higher levels of genetic 
instability and a higher probability of liver cancer when present in a non-cancerous 
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liver, scientists have constructed transgenic mice that exhibit similar genotypes 
found in human cancer. Ghebranious and Sell [31] constructed transgenic mice 
that were both homozygous and heterozygous for the p53ser246 gene, equivalent 
to the human p53 249ser mutations. Male mice expressing p53ser246 increased the 
incidence of AFB1-associated high-grade tumors to 14%, compared to 0% exhibited 
by p53+ (wild type) mice [31]. These studies indicate that the mutant p53 249ser may 
also be a driver of AFB1-associated liver cancer.
The role of inflammation in liver cancer has led to insights into the gender bias 
of its incidence. Men are afflicted more than women in nearly all age groups; how-
ever the prognosis of liver cancer in either sex is about the same [9]. Naugler et al. 
[18], have shown that inflammatory cytokines, such as IL-6, are more prevalent in 
men than women, estrogen having a negative effect on IL-6 production. This gender 
difference is not only true for humans [32, 33] but also for rodents, including mice 
and rats [31]. The gender bias underscores the notion that inflammatory responses 
play a role in liver cancer etiology.
2.2 Associated risk factors that accelerate AFB1-associated liver cancer: role  
of HBV and HCC virus
The incidence of HCC synergistically increases when individuals are both 
exposed to AFB1 and infected with either HBV or HCV virus. Interestingly, the inci-
dence of high grade tumors in p53ser246 transgenic mice that are HBsAg-positive is 
100% [31]. The common molecular mechanisms by which HBV and HCV infection 
stimulates AFB1-associated genetic instability phenotypes are still not completely 
understood; HBV is a DNA virus that replicates by reverse transcription while HCC 
is a RNA virus that replicates by RNA replication and encodes a single polycistronic 
message [34, 35]. While 257 million individuals are estimated to be infected with 
HBV, 140 million individuals are estimated to be infected with HCV; and chronic 
HBV and HCV infection is the leading cause for 60–70% of HCC [35, 36]. Although 
HCC contains no oncogenes per se, HCV-associated carcinogenesis is associated 
with increase in reactive oxygen species (ROS), ROS-associated genetic instability, 
inflammation, and hepatocyte proliferations [36]. Similarly, HBV-associated HCC 
is associated with inflammation and necro-inflammatory liver damage [16, 36]. 
Both viruses are not cytopathic per se; liver damage caused by HCV and HBV is 
likely induced by viral-specific CD8+ T and natural killer cells (NK) [35, 36]. Thus, 
both HCV and HBV create an inflammatory cellular environment that stimulates 
repopulation of hepatocytes, enhancing AFB1-associated genetic instability.
However, different pathologies of HBV and HCV infection may accelerate HCC 
progression at different rates. While the median onset age for HBV-associated HCC 
is 55 years that of HCV is 65 years [11]. HBV can chronically infect children after 
transmission from the mother [11, 36]. Once HBV is stably integrated into the host 
genome, HBV can promote chromosomal rearrangements and mutations in cancer-
associated genes and interfere with checkpoint controls [37, 38]. For example, HBV 
integration can occur in TERT promoters, stimulating expression of telomerase, 
and near LINE sequences [39]. The HBV-encoded oncogene HBx can activate 
both Src and Ras signaling and is essential for viral DNA (cccDNA) replication. 
To facilitate replication, HBx mediates chromatin changes by recruiting histone 
acetyltransferases to acetylate histone H3. HBx is also thought to interact with p53 
249ser, and attenuate DNA repair and apoptosis [20].
Besides stimulating host cell replication, HBx may also interfere with the host 
cell’s DNA repair pathways and promote genetic instability and replication [38, 
40–44]. HBx binds to DNA damage binding protein 1 (DDB1) and cullin-4 (Cul4), 
which form a ubiquitinase complex, and can perturb the stability of structural 
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maintenance of chromosome proteins 5 and 6 (Smc5/6) and thus affect DNA 
replication and DNA damage tolerance [35]. HBx may also interfere with nucleotide 
excision repair (NER) of AFB1-associated DNA adducts [40–42, 44]. Although less 
substantiated, HBx is also thought to interfere with PARP1 and decrease excision 
repair of DNA adducts. Thus HBx drives carcinogenesis by multiple mechanisms 
that accelerate carcinogenesis.
2.3 Gene polymorphisms associated with AFB1-associated liver cancer
While HBV and HCV infections are the primary factors that aggravate the risk 
for AFB1-associated HCC, genetic risk factors have also been postulated [45]. With 
the advent of technologies that accelerate genome sequencing, such as next genera-
tion sequencing (NGS), epidemiologists have identified candidate polymorphic 
genes that increase the risk for aflatoxin-associated liver cancer. Single nucleotide 
polymorphisms (SNPs) may be located in the amino acid coding region, the 
introns, or the promoter regions of the candidate genes. Risk factors generally can 
be grouped into those that (1) are associated with AFB1 metabolic activation and 
detoxification and (2) that function in DNA repair or DNA damage tolerance genes.
To understand genetic risk factors that affect metabolic activation and detoxifi-
cation of AFB1 it is necessary to identify genes involved in these pathways. AFB1 is 
activated by cytochrome P450 enzymes that hydroxylate AFB1 so that the metabo-
lized carcinogen can be rendered hydrophilic and effectively excreted; for review, 
see [46–48]. Referred to as phase I enzymes and monooxygenases, the cytochrome 
P450 enzymes contain a heme group at their active sites and catalyze the transfer 
of single oxygen to specific sites on the target molecule [46]. Cytochrome P450 
enzymes require NADPH oxidoreductase (POR) to maintain activity [46]. The 
P450 enzymes are located in the endoplasmic reticulum in the vicinity of the POR 
[46]. Of the characterized enzymes expressed by 57 CYP450 genes, CYP1A2 is liver 
specific and has a high affinity for AFB1, while CYP3A4 constitutes approximately 
50% of the hepatic P450 activity. While there have been disagreements over which 
cytochrome P450 enzymes is chiefly responsible for AFB1 activation in the liver [46, 
49, 50], several reports favored CYP3A4 [50, 51], while another report suggested 
that CYP3A5 has the highest catalytic activity [52]. Among extrahepatic CYPs, 
CYP2A13 activates AFB1 in the lung, while CYP1A1 catalyzes the formation of 
AFM1, a hydroxylated AFB1 derivative that can be excreted in milk, which is  
still carcinogenic [2]. A transient intermediate in the hydroxylation pathway is  
a highly reactive epoxide, referred to as AFB1-8,9-exo-epoxide (AFBO) (Figure 1).  
This epoxide can be effectively detoxified by either epoxide hydrolases (EHs) 
or glutathione S-transferases (GSTs), referred to as phase II enzymes [47, 48]. 
While multiple cytochrome P450s can activate AFB1, the highly reactive epoxide 
is thought to be the predominant reactive intermediate in all P450 reactions. Thus, 
gene polymorphisms that increase the risk of HCC could: (1) increase P450 enzyme 
levels or activation, (2) downregulate phase II enzymes, (3) decrease the repair of 
DNA existing lesions, and (4) channel the repair of the DNA lesions into mutagenic 
pathways.
One source of polymorphic enzymes that can influence the fate of AFB1 is glu-
tathione S-transferases that are present in the liver [53]. In the mouse, knock-out of 
GSTa3 confers extreme AFB1-associated toxicity [54] and GSTa3 expression levels 
correlate with AFB1-associated liver cancer in young mice [55]. In humans, HCC 
risk is dramatically increased by SNPs in glutathione S transferase mu1 (GSTMI) 
and (glutathione-S-transferase theta1) (GSTT1) [56]. Expression of epoxide 
hydrolase in yeast also leads to detoxification of AFBO [57]; however, polymor-
phisms associated with epoxide hydrolase only have a weak association with liver 
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cancer [45]. These studies support the idea that detoxification of the highly reactive 
epoxide is critical in reducing AFB1 toxicity.
While diminished ability to detoxify AFBO is a risk factor for AFB1-associated 
liver cancer, higher or altered P450 activity could also increase HCC risk. HBx 
activates the pregnane receptor (PXR) and stimulates expression of CYP3A4 [58]. 
Particular CYP3A5 alleles, such as CYP3A5*3, are correlated with higher levels of 
expression and aflatoxin-protein adducts in individuals from Gambia, Africa [59]. 
CYP3A5*3 is present in a high percentage of individuals in Gambia but not in the 
Caucasian population [59]; the allele found in the Caucasian population confers an 
altered spliced mRNA, which is poorly expressed [60]. However, establishing cor-
relations between HCC and increased expression of other P450 genes is complicated 
by the multiple interactions between P450 enzymes.
Genetic risk factors have also been identified among polymorphic alleles of 
DNA repair and cell cycle checkpoint genes, which may increase chromosomal 
instability in cells chronically exposed to AFB1. These risk factors have been found 
in p53, XRCC1, XRCC3, and ERCC1. The combination of p53 codon 72 Arg72Pro 
and MDM2 (mouse double minute 2 homolog) SNP309 (T>G) increases the risk 
of HCC in individuals infected with HBV [61]; p53 codon 72 Arg72Pro affects the 
frequency of double strand breaks and is associated with hyper-methylation of 
promoters in tumor suppressor genes [61]. XRCC3 (X-ray complementing defec-
tive repair in Chinese hamster cells) encodes a Rad51 paralog which is involved in 
double-strand break repair and could be involved in error-free by pass of AFB1-
associated DNA lesions. The XRCC3 rs861539 allele (codon Thr241Met polymor-
phism) is a risk factor for HCC, and the risk is aggravated if individuals are exposed 
to AFB1 [62–64]. Other alleles that have been associated with higher risk for HCC 
include those participating in the base excision repair (BER) and NER pathways, 
such as XRCC1 rs25487 polymorphism (codon Arg399Gln polymorphism) [65, 66] 
and XPD rs25487 polymorphism, respectively [67]. These studies reinforce the idea 
that AFB1-associated genotoxicity can accelerate HCC progression. To understand 
the genotoxicity in more detail it is important to understand the nature of the AFB1-
associated DNA adducts.
Figure 1. 
CYP-mediated metabolic activation of AFB1 to the activated AFB1-8,9 epoxide and adduct formation and 
conversion to AFB1-Fapy. Adapted from Ref. [130].
7Cellular Responses to Aflatoxin-Associated DNA Adducts
DOI: http://dx.doi.org/10.5772/intechopen.81763
2.4 AFB1-associated DNA adducts and cellular targets
AFB1-associated DNA adducts have been characterized in vitro and isolated 
from organisms that were exposed in vivo. DNA exposed to synthesized AFBO 
reacts predominately with the N7 group of guanine bases forming 8,9-dihydro-
8-(N7-guanyl)-9-hydroxyaflatoxin B1 (AFB1-N7-Gua), as identified by mass spec-
trometry analysis. In the presence of hydroxyl ions (base), N7-guanine DNA adduct 
is unstable and decays into an apurinic site and a AFB1 formamidopyrimidine (Fapy, 
Figure 2) DNA adduct; for review, see [68]. It is unclear whether both apurinic sites 
and AFB1-Fapy DNA adducts are equally generated; based on mutations generated 
by DNA lesions constructed in vitro, it has been suggested that AFB1-Fapy DNA 
adducts are the primary source of genetic mutations [69, 70], especially G to T 
transversion mutations that are found in AFB1-associated liver cancer [71, 72]. The 
AFB1-Fapy adduct is stable and can be present in two anomer forms; the alpha and 
the beta forms. While the beta form is highly mutagenic in Escherichia coli [69], the 
alpha form can stabilize the duplex helix and interfere with DNA replication [70]. 
In the rat liver, the half-life for AFB1-N7-Gua is 7.5 h, while that for AFB1-Fapy is at 
least 24 h [68]. While the AFB1-N7-Gua is unstable, the accumulation of AFB1-Fapy 
in the rat liver may also result from differential repair of the two types of DNA 
adducts.
AFB1 exposure also generates oxidative stress (ROS) in exposed cultured cells 
in vitro and in the liver and lung in vivo [73]. Multiple factors may contribute to 
Figure 2. 
Intercalation of the AFB1-Fapy-dG in duplex DNA. The adduct is in lighter tone; adapted from Ref. [121].
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AFB1-associated oxidative stress including cytochrome P450 activity that involves 
iron-catalyzed reactions and Kupffer cells [68]. Oxidative stress generates hydroxyl 
radicals that form 8′-hydroxy-2′-deoxyguanosine (8oxodG) DNA damage. AFB1 
exposure increases the 8OH-dG in the livers of ducks [74] and rats [75] and cultured 
woodchuck hepatocytes [68].
Interestingly, Niranjan et al. [76] observed that in rats, AFB1 bound to 
mitochondria l DNA exceeded the amount that was bound to the nuclear DNA 
and persisted for a longer period of time [76]. Furthermore, the persistence of 
mitochondrial DNA adducts correlated with a longer delay in expression of mito-
chondrial proteins, compared to that of nuclear-encoded proteins. The authors 
speculated that the persistence of AFB1 in the mitochondria may result from the 
lack of NER in the mitochondria. These studies support the notion that mitochon-
dria are a prime target for acute effects of AFB1 exposure, and oxidative stress 
associated with AFB1-exposure could be indirect due to damage to mitochondria 
and the generation of superoxide.
To further elucidate the pathological consequences of AFB1-associated 
mitochondrial DNA lesions, Liu and Wang [77] measured AFB1-associated mito-
chondrial damage in primary broiler hepatocytes by monitoring mitochondrial 
membrane potential (MMP), ROS generation, apoptosis, and nuclear factor ery-
throid 2-like factor 2 (Nrf2)-related signal pathway. They observed mitochondrial 
ROS generation, decreased MMP and induced apoptosis. The increase in apoptotic 
cells correlated with an increase expression of caspase-9 and caspase-3. They 
concluded that AFB1 exposure results in a disruption of mitochondrial functions, 
generating more ROS, and consequently inducing apoptosis while triggering the 
Nrf2 signaling pathway [77].
2.5 Epigenetic changes associated with AFB1-associated damage
While genetic instability associated with AFB1 have been described, less well 
known are epigenetic changes. Epigenetic changes are inheritable changes that 
result in phenotypic changes without affecting the DNA sequence. Epigenetic 
changes can result from DNA methylation (hypermethylation) or demethylation 
(hypomethylation), histone modifications, and changes in microRNA (miRNA) 
expression [78]. AFB1-associated epigenetic changes have been observed in cell 
cultures, animal studies, and human tumors (Table 1). Hypomethylation has been 
observed to increase the expression of oncogenes and repetitive sequences, while 
hypermethylation may decrease expression of DNA repair and tumor suppressor 
genes (Table 1). Zhang et al. [79] observed global hypomethylation in AFB1-
associated cancers, where particular genomic repetitive elements, such as LINE-1 
elements, were hypomethylated; correlating with increased retro transposition and 
genetic instability [80]. Hypomethylation also correlated with increased expression 
of the oncogene c-MET, which is associated with accelerated liver cancer progres-
sion and poor prognosis [81]. Hyper-methylated genes include the DNA repair gene 
methylguanine methyl transferase (MGMT) and p16, which have a negative effect 
on DNA repair and apoptosis [82]. Thus, methylation patterns may possibly serve as 
biomarker that can indicate increased risk for HCC [83–85].
Additional biomarkers that indicate AFB1 exposure include alterations in 
miRNA expression. miRNAs are small noncoding RNAs that are generally 19–25 
nucleotides in length and regulate gene express at the post-transcriptional level. 
They are important factors in regulating HCC development in mammalian organ-
isms [87, 88], and a list of miRNAs that correlate with AFB1 exposure is shown in 
Table 1. This comprises a partial group of total miRNAs that have been associated 
with HCC. Several miRNAs upregulated after rats or liver cell lines are exposed to 
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Epigenetic change Gene functions affected Consequence Context/ref.
DNA methylation
DNA hyper methylation MGMT expression decreased DNA Repair downregulated Human tumor tissue [82]
DNA hypo methylation c-MET, RAB27A, TXNRD1 expression increased
LINE 1
Growth and metastasis increased, decreased expression  
of GSTs, LINE1 transposition increased
Human tumor tissue [79, 81, 82]
miRNA expression
miR-429 Downregulates Rab23 Metastasis increased when miR-429 decreased HCC tumor tissue [83, 85]
miR-4-34a Downregulation of WNT/β-catenin pathway Tumor suppressor effect; p53 enhances its expression HepG2 cell lines [83]
miR-33a Downregulation of WNT/β-catenin pathway Tumor suppressor effect; p53 enhances its expression HepG2 and normal cell lines [83]
miR-24 Inhibition of apoptosis Larger tumor size HCC tumor tissue [83]
miR-34a-5p c-MET, CCND1, CCNE2 suppressed Cell cycle arrest In vivo rat livers [83]
miR-122 CUTL1 suppressed in mice Required for tumor differentiation Human studies [83, 88]
miR-138-1* PDK1 and indirectly PI3K/PDK/Akt Inhibits colony formation, migration, invasiveness P450-B-2A13 human cell culture 
[83]
Histone modification
H3K9me3 Repression of gene expression (multiple) Reprogramming of pluripotency Porcine oocytes [83]
H3K27me3 Repression of gene expression (multiple) Developmental gene programing in stem cell differentiation Porcine oocytes [83]
H3K4me2 Activating gene expression (multiple) Developmental gene programing in stem cell differentiation Porcine oocytes [83]
, up arrow designates upregulation; , down arrow designates down regulation.
Table 1. 
Epigenetic changes associated with AFB1 exposure.
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AFB1 may be protective by downregulating cell proliferation, while upregulated 
miRNAs found in AFB1-associated HCC may promote tumor size or carcinogen-
esis. While an individual microRNA may target multiple genes, the expression of 
individual microRNA can be influenced by multiple transcriptional and epigenetic 
factors, as well as by genomic changes. These factors include CpG methylation, 
c-Met signaling, and gene copy number.
Among HCC tumor cells associated with AFB1 exposure, upregulation of 
several miRNAs, such as miR-429 and miR-24 [86], are associated with larger 
tumor size [83]. In human bronchial epithelial cells that express CYP2A13 (P50-
B-2a13 CELLS), AFB1 exposure induces malignant transformation of immortalized 
cells [89]. Among transformed cells, one downregulated miRNA was miR-138-1, 
observed to inhibit proliferation, colony formation, and transformation of P50-
B-2a13 CELLS [89]. This miRNA preferentially inhibits 3-phosphoinositide depen-
dent protein kinase-1 (PDK1), which lowers the expression of the P13K/PDK/Akt 
pathway [89]. These studies indicate that changes in miRNA expression in AFB1-
associated HCC may promote carcinogenesis.
HBV infection also upregulates the expression of miRNAs in hepatocytes and 
may promote HBV-associated HCC. The expression of miR106b-25 is upregulated 
in HCC patients in general, and in HCC patients infected with HBV [90]. Hep 3B 
cells transformed with an HBx expression plasmid also express higher levels of 
miR106b-25, compared to cells that do not express HBx. The miR106b-25 is a mem-
ber of a cluster of miRNAs in MCM7 that downregulate the expression of several 
tumor suppressors, including p21, E2F, BIM, and pTEN [91]. Thus, HBV infection 
may not only interfere with DNA repair mechanisms but also epigenetically silence 
tumor suppressor genes and accelerate HCC progression.
2.6 Mutagenic signatures associated with AFB1-associated DNA adducts
Mutation signatures are useful biomarkers to determine AFB1 exposure and 
HCC progression. AFB1 is known to induce mutations in E. coli, Saccharomyces 
cerevisiae (budding yeast), and in mammalian cells. AFB1 was one of the original 
carcinogens published in the Ames assay [92, 93]. While G to T transversions are 
considered associated with chronic AFB1 exposure in humans [19, 20, 68, 71], in E. 
coli, carcinogen-induced transversion mutations require over-expression of expres-
sion of MucAB, which encodes the polV error-prone polymerase [94]. In budding 
yeast expressing either human CYP1A2 or CYP1A1, AFB1 has been shown to 
increase mutation frequencies at a CAN1, LYS2, and URA3; however the mutagenic 
signature of AFB1 in yeast has yet to be identified [95, 96]. The mutagenicity of 
AFB1 in yeast, however, is low compared to many alkylating agents, such as ethyl 
methane sulfonate (EMS) [95].
While AFB1 is well-known to cause G to T transversion mutation in mammalian 
cells, other nucleotide substitutions occur, some of which are in the vicinity of 
the AFB1-DNA adduct. Investigators have used two approaches to determine the 
DNA sequence context of AFB1-associated mutations; one technique utilizes PCR 
(QPCR) and ligation-mediated PCR (LMPCR), and the second technique utilizes 
whole genome sequencing. Using the first technique, Denissenko et al. [97] mapped 
total AFB1 adducts in genomic DNA treated with AFB1-8,9-epoxide. In a second 
experiment, Denissenko et al. [97] mapped total AFB adducts in hepatocytes 
exposed to either AFB1 activated by rat liver microsomes or AFB1 activated by 
human liver microsomal preparations. The p53 gene-specific adduct frequencies in 
DNA, modified in cells with 40–400 μM AFB1, were 0.07–0.74 adducts per kilobase 
(kb). In vitro modification with 1–4 ng AFB1-8,9-epoxide per microgram DNA 
produced 0.03–0.58 lesions per kb. The adduct patterns obtained with the epoxide 
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and the different microsomal systems were virtually identical indicating that AFB1 
adducts share similar sequence-specificity whether occurring in vitro and in vivo.
With the advent of next generation sequencing (NGS) [98], investigators have 
studied the entire genome and determine whether particular mutation signatures. 
Huang et al. [99] determine whole genome sequencing data to determine the 
position of >40,000 mutations in two human cell lines, and in liver tumors from 
wild type mice and a transgenic mouse carrying the hepatitis B surface antigen. 
The mutational signature from all four experimental systems was remarkably 
similar and compared well with experimental mutational signatures derived from 
sequenced HCCs form Qidong County in China, an area of high AFB1 exposure 
[100]. The Catalog of Somatic Mutations in Cancer (COSMIC) mutational signature 
24 [101], previously associated with AFB1-associated liver cancer, was confirmed 
and also shown to be present in a high proportion (16%) in HCC from Hong Kong, 
but in 1% or less from HCC from Japan or North America. The COSMIC mutation 
signature 24 indicates guanine damage with a very strong transcriptional strand 
bias for C>A mutations. Additional studies being performed by multiple research 
groups [25, 102] confirm the presence of signature 24 in human HCC tumors and in 
tumors induced by AFB1 in mice. In addition to signature 24, investigators have also 
noted the presence of transition mutations that might also occur in the context of 
oxidative stress. It has not been determined which of these minor mutation classes 
drive HCC.
2.7 AFB1 is a potent recombinagen
In budding yeast expressing CYP1A2, AFB1 is potent recombinagen but a poor 
mutagen [95]. Exposure to AFB1 stimulates homologous recombination between 
sister chromatids (sister chromatid exchange or SCE), chromosome homologs, 
and repeated sequences located on non-homologous chromosomes. Using a 
recombination assay involving truncated fragments of his3 [103] positioned on 
non-homologous chromosomes, Sengstag et al. [95] showed that homologous 
recombination could be stimulated 50-fold in contrast to a less than 10-fold stimu-
lation of mutations. AFB1 concentrations as low as 5 μM were shown to be effective 
at stimulating the formation of reciprocal translocations, and the karyotypes were 
confirmed by pulse field gel electrophoresis [103]. AFB1 is also a recombinagen in 
human and Chinese hamster ovary (CHO) cells and can increase the frequencies 
of SCE [104–107]. It is unclear whether the same AFB1-associated DNA lesions can 
stimulate both mutations and recombination. For example, it could be possible that 
particular lesions that stall DNA replication and generate breaks generate more 
recombination events while other lesions that can be bypassed by DNA polymerases 
generate more mutagenic events. These studies thus demonstrate that the genotox-
icity of AFB1 extends beyond making mutations and involves stimulating chromo-
somal rearrangements in model eukaryotic organisms and in humans.
2.8 Repair of AFB1-associated DNA damage
Considering the genotoxicity of AFB1-associated DNA adducts and possible 
hindrance of DNA replication, it is important to identify which DNA repair pathways 
and which replication bypass mechanisms are used to tolerate the most persistent 
AFB1-associated DNA adducts. There are several pathways that are involved in 
repairing AFB1-associated DNA damage. Among these repair pathways are nucleotide 
excision repair NER, BER, and recombinational repair; for a general review see [108]. 
Post-replication repair pathways to bypass DNA adducts involve (1) either error-
prone or error-free DNA polymerases, or (2) template switch mechanisms. The later 
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mechanism involves DNA recombination mechanisms, which are utilized in tolerat-
ing UV-induced DNA damage and alkylated DNA bases. While in some organisms 
there are preferred pathways, a general theme in DNA repair is that organisms have 
evolved redundant DNA repair mechanisms. A prediction of redundant DNA repair 
pathways is that eliminating genes in two or more repair pathways should effectively 
lead to a synergistic decrease in AFB1 resistance, while eliminating genes in the same 
pathway should confer no greater sensitivity than the most sensitive mutant.
Nucleotide excision repair (NER) involves the recognition of the DNA adduct, 
the opening of the helix at the DNA damage site, the excision of the DNA adduct 
and the re-synthesis of DNA using the non-damaged DNA strand as a template. In 
general, 12–13 nucleotides are excised in prokaryotes (for review see [109]) while 
24–32 nucleotides are excised in eukaryotes. Global genome repair (GGR) can occur 
on either the transcribed or non-transcribed strand. Transcription-coupled repair 
(TCR) does discriminate and preferentially repairs the transcribed strand. The 
mechanistic difference between the two pathways is how the DNA adduct is recog-
nized; in GGR specific proteins recognize the DNA helical distortion while in TCR, 
the RNA polymerase stalled complex is recognized; for general review see [110]. In 
eukaryotes and prokaryotes, both mechanisms are used. While the mechanism is 
widely conserved among eukaryotes, the mechanism differs between prokaryotes 
and eukaryotes in the amount of DNA that is excised.
NER is likely to be the predominant mechanism for the repair of AFB1-
associated DNA damage in many eukaryotic and prokaryotic organisms [68]. The 
AFB1-N7-guanine adduct is fairly unstable while the AFB1-Fapy DNA adduct can 
insert between the base pairs of the DNA double helix [111]. UvrABC from E. coli 
can effectively excise both DNA adducts, although the AFB1-Fapy adduct appears 
to be more chemically stable [68, 112]. The excision of the DNA adducts does not 
depend on the SOS response; thus, basal levels of the DNA repair enzymes appear 
to be adequate in repairing the DNA lesions. In E. coli, both AFB1-N7-Gua and 
AFB1-Fapy adduct appear to be excised at a similar rate. One explanation is that the 
UvrABC complex does not rely on helix distortion to repair the DNA adduct, but 
rather size and structure of the aromatic rings [68, 112].
Other insights from model organism yeast revealed that the NER genes are 
required to excise AFB1-associated DNA adducts [96, 113, 114]. RAD14 (XPA) and 
RAD1-RAD10 (XPF-ERCC1) are required for AFB1 resistance. Failure to repair the 
DNA adducts in a rad4 (XPC) haploid mutant results in S phase arrest, support-
ing the notion that particular AFB1-associated DNA adducts interfere with DNA 
replication [113, 114]. In addition, in rad4 mutants the level of AFB1-N7-Gua DNA 
adducts was reported to increase three fold [114]. These studies support the notion 
that the yeast NER pathway recognizes and repairs AFB1-N7-Gua DNA adducts.
In mammalian cells, the NER pathway preferential repairs AFB1-N7-Gua DNA 
adducts but still participates in the repair of AFB1-Fapy DNA adducts [115, 116]. In 
XPA human fibroblast cells, the loss of AFB1-N7-Gua DNA is much slower and the 
accumulation of the AFB1-Fapy DNA adducts is greater compared to wild type cells 
[116]. XPA−/− deficient mice are also more susceptible to AFB1-associated tumori-
genesis compared to wild-type mice [117]. Since the accumulation of DNA adducts 
correlate with the increased carcinogenicity of the DNA adducts [71, 72, 118], it is 
likely that the burden of AFB1-associated DNA adducts increases the frequencies of 
carcinogen-associated mutations in the XPA deficient mice.
The second major pathway to repair DNA involves the BER pathway (for review, 
see Fortini and Dogliotti [119]). As in NER, the DNA damage base is excised and new 
DNA is synthesized using the undamaged DNA as template for repair (Figure 3). 
In BER, the modified DNA base is recognized and excised by a specific enzyme that 
generally referred to as a glycosylase. Subsequently, a apurinic endonuclease (APE1) 
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generates a 3′OH for primer recognition and new DNA synthesis. In mammalian cells, 
polymerase β synthesizes new DNA across the gap and removes the deoxyribose resi-
due, and XRCC1/Ligase III cooperate to seal the nick An alternative pathway that does 
not involve APE1, employs endonuclease VIII like-1 (NEIL1). Following excision of the 
damaged base by a βδ excision mechanism, the 3′ phosphate is excised by polynucleo-
tide kinase (PNK) to yield a 3′OH for primer recognition and new DNA synthesis. 
For long patch repair, DNA polymerase δ/PCNA/RFC synthesizes across the gap, the 
displaced oligonucleotide is excised by FEN1, and the nick is sealed by Ligase I [119]. 
Poly(ADP-ribose) polymerase PARP1 generally protects the single-strand gap from 
being subjected to further cleavage or from serving as a substrate for recombinational 
repair proteins although additional pathways have been proposed [120].
Interestingly, while BER mechanisms have been thought to play a minor role for 
DNA repair of some AFB1-associated DNA adducts in yeast, BER mechanisms for 
AFB1-associated DNA adducts can occur in mammalian cells. In budding yeast, the 
apn1/apn2 haploid double mutant is no more AFB1 sensitive than the haploid wild 
type [96]. However, AFB1-associated mutagenesis is lower in the apn1/apn2 haploid 
double mutant compared to wild type [96], suggesting that either Apn1 or Apn2 
still function in processing the AFB1-associated adducts for post-replication repair. 
One interpretation of these results is that there is redundancy in both NER and BER 
mechanisms for conferring AFB1 resistance, while another interpretation is that 
budding yeast lack the BER enzymes, such as NEIL1, which may actively participate 
in the repair of AFB1-associated DNA adducts.
In mice, the NEIL1 gene has been isolated and knock-out of the gene leads to 
higher levels of AFB1-associated DNA adducts and AFB1-associated HCC [121]. 
The NEIL1 enzyme recognizes and excises AFB1-Fapy-dG adducts in “bubble” 
DNA structures, such as the one described by Brown et al. [70, 111]. One idea is 
that AFB1-Fapy-dG adducts may stably intercalate in the helix and be recognized by 
NEIL1-dependent BER pathway but not by the NER pathway; the repair pathway 
may thus depend on the DNA sequence context of the AFB1-Fapy-dG adduct. 
Knock-out of NEIL1 in mice leads to an increase of AFB1-associated tumors and 
Figure 3. 
BER (left) and NER (right) mechanisms to repair the AFB1-Fapy adduct. Both mechanisms involve incision 
and excision of the damage base, followed by unscheduled DNA synthesis.
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an accumulation of Fapy-adducts [121]. Vartanian et al. [121] assert that the 
AFB1-associated carcinogenicity in Neil1−/− mice is as high if not higher than that 
observed in Xpa−/− mice, noting that both the size and number of tumors are 
greater in the Neil1−/− mice compared to the Xpa−/− mice. However, the investigators 
indicate that spontaneous tumors arise at a much higher frequency in Xpa−/− mice, 
so that the increase in AFB1-associated tumors were measured until the mice were 
11 months in age and not when the mice were 15 months in age.
AFB1 exposure is also associated with oxidative stress, as evident by the accumula-
tion of 8-oxodG lesions. It is particularly interesting whether 8-oxodG accumulates 
in particular DNA repair mutants and contributes to genotoxicity and the etiology 
of liver cancer. The contribution of 8-oxodG to overall AFB1-associated genotoxicity 
is unclear; Ogg1−/Ogg1− transgenic mice do not exhibit more AFB1-associated lung 
tumors than those that are wild type, but do exhibit increased weight loss and mortal-
ity [122]. However, Ogg1−/− null mice succumb to other cancers after being exposed to 
oxidizing agents and carcinogens [123]. These studies suggest that AFB1-associated 
8-oxodG lesions are not the causative lesions in liver or lung cancer.
The third major pathway in cells that function in AFB1-associated DNA damage 
is recombination repair. Knocking out RAD51 in either rad14 or rad4 cells leads 
to a synergistic increase in AFB1 sensitivity in yeast [96, 113]. There are two dif-
ferent explanations. One explanation is that some AFB1-associated DNA lesions 
that accumulate in rad4 cells are converted into single or double-strand breaks and 
require recombinational repair. A single double-strand break has previously been 
shown to be lethal in strains defective in homologous recombination [124]. An 
alternative explanation is that cells require RAD51 to bypass the DNA lesions and 
accumulate stalled replication forks. Studies have shown that RAD51 is required 
for DNA damage-associated SCE [125], which likely occur by replication bypass 
mechanisms. This second reason is also supported by the notion that rad4 cells tend 
to arrest in a small budded stage upon entry into the cell cycle.
2.9 DNA damage tolerance and AFB1-associated DNA damage
DNA damage tolerance pathways allow cellular replication mechanisms to bypass 
blocking DNA adducts, such as the AFB1-Fapy DNA adduct, resulting in persistence 
of the DNA adduct in the divided cells. These mechanisms are divided into error-free 
mechanisms where the original “correct” base is opposite the modified base and 
error-prone mechanisms where an “incorrect” base is inserted opposite the damaged 
base, thereby generating mutations. The insertion of the “incorrect” base is gener-
ally accomplished by substituting a “high fidelity” polymerase with a lower fidelity 
polymerase that also has lower processivity. The polymerase switch mechanism is 
accomplished by a series of ubiquitination reactions on PCNA, which is the proces-
sivity factor for DNA polymerase on the DNA template; for review, see [126, 127]. 
The first ubiquitination reaction of PCNA is a monoubiquitination reaction catalyzed 
by Rad18/Rad6. Subsequent polyubiquitination of PCNA by Rad5/Ubc13/Mms2 is 
required for error-free by-pass mechanisms, which includes template-switch mecha-
nisms. Both RAD18/RAD6 and RAD5 genes are well conserved in eukaryotes.
The function of replication bypass in conferring AFB1 resistance has been 
validated in model organisms. In budding yeast, RAD18, RAD5, REV1, and REV7/
REV3 are required for AFB1 resistance [96]. These genes are also required for AFB1-
associated mutagenesis [96]. These results indicate that all three translesion poly-
merases are required for AFB1 resistance, while it is unclear which gene is required 
for replication bypass of individual AFB1-associated DNA adduct.
While there are only three translesion DNA polymerases in budding yeast, in 
humans, there are at least 11 translesion polymerases, forming the majority of the 15 
DNA template-dependent DNA polymerases [128]. Both the AFB1-N7-Guanine and 
15
Cellular Responses to Aflatoxin-Associated DNA Adducts
DOI: http://dx.doi.org/10.5772/intechopen.81763
the AFB1-Fapy DNA adducts can be bypassed by translesion polymerases [129, 130]. 
Of the translesion polymerases, DNA polymerase ζ, also referred to as Rev3L the Rev3 
homolog in humans, limits chromosomal damage and promotes cell survival follow-
ing AFB1 exposure [131]. The authors suggest that Rev3 is required for progression 
through S phase since mouse embryonic fibroblasts, derived from Rev3L−/− knock 
down mice, arrest in S/G2 after AFB1 exposure [131]. These cells also exhibit an 
increase in gamma-H2AX foci, micronuclei, and chromosomal aberrations; the kinet-
ics of micronuclei formation support a replication-dependent mechanism that results 
in the accumulation of unrepaired DSBs in. The Rev3 requirement for DNA replication 
of an AFB1-associated DNA adduct was also demonstrated for a single lesion present 
on a replicating plasmid in HEK239 cells [131]. Considering the number of mammalian 
translesion polymerases [128], the Rev3 requirement for replication bypass may reflect 
the efficiency by which AFB1-associated DNA adducts block other polymerases or 
Rev3’s ability to minimize detrimental chromosomal damage [132].
2.10  Template-switch mechanisms as an alternative mechanism for tolerating 
DNA damage
Exposure to AFB1 stimulates SCE in multiple organisms. One possible mechanism 
is that in post-replication repair, processing of AFB1-associated DNA damage gener-
ates apurinic sites and/or subsequent DNA single-strand gaps, which initiate SCE by 
serving as substrates for DNA recombination proteins. Template switch mechanisms 
are another mechanism (Figure 4) that avoid the necessity of using error-prone 
polymerase for replication bypass. In support of the role of template switching in 
AFB1-associated SCE, studies have been performed in budding yeast indicating that 
rad51 null mutants, deficient in DNA damage-associated SCE [125], exhibit higher 
frequencies of AFB1-associated mutations [96, 133]. In addition, Rad51 foci appear as 
cells enter S phase [114] and not in G2, suggesting that the appearance of Rad51 foci 
are replication-dependent and not associated with double- or single-strand breaks 
after replication. However, it is possible that multiple mechanisms are involved.
AFB1-associated SCE are also observed in human and mammalian cells. SCEs 
have been detected in human lymphocytes, Chinese hamster V79 cells, rat and 
mouse hepatocyte cell lines [104–107]. It has not yet been determined whether 
mammalian cells defective in homologous recombination exhibit more AFB1-
associated mutations. Nonetheless, it is interesting that polymorphisms of XRCC3 
[62–64], which functions in homologous recombination, are a risk factor for HCC.
2.11 Tissue specificity of DNA damage repair of AFB1-associated DNA adducts
Since AFB1-associated DNA adducts are found in different tissues, the question 
can be asked whether there are tissue-specific differences in repair mechanisms. 
Mudler et al. [134] addressed the question whether oxidative damage caused by AFB1, 
8-oxodG, was repaired more efficiently in the mouse lung compared to the mouse liver. 
They exposed mice to a low chronic amount of AFB1 (0.2 or 1.0 ppm AFB1) and then 
assayed for the amount of dGTP incorporation. Interestingly, they found that although 
Ogg1 was present in both the lung and the liver, there was a lower repair efficiency in 
the liver after exposure to 1.0 ppm AFB1. The lower efficiency of the repair in the liver 
did not correspond to AFB1-associated cytotoxic effects, and they speculated that the 
differences could result from AFB1 directly inhibiting Ogg1 [134].
Bedard et al. [135] asked the question whether AFB1-N7-Gua and AFB1-Fapy 
DNA adducts were repaired more efficiently in the mouse liver or lung. They also 
compared the efficiency of repair in the rat liver and the mouse liver. After exposing 
mice to 50 mg/kg AFB1, extracts were obtained from the various tissues and used 
to determine the repair of plasmid DNA AFB1-N7-guanine or AFB1-Fapy adducts as 
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substrates. Mouse liver extracts repaired AFB1-N7-guanine and AFB1-Fapy adducts 
5- and 30-fold more effectively, respectively, than did extracts from the mouse lung. 
Mouse liver extracts also repaired the adducts 6-fold and 4-fold more effectively, 
respectively, than did liver extracts from rats. They conclude that there is a tissue-
specific induction in repair in the mouse liver that renders the mouse liver more 
resistant to AFB1-associated carcinogenesis. However, further studies are needed to 
determine which NER and BER enzymes are preferentially induced in the liver.
2.12 AFB1-induction of DNA repair and protective mechanisms
The redundancy in repair mechanisms for DNA adducts in yeast and in mamma-
lian organisms provokes the question of which genes are transcriptionally induced 
after the exposure of AFB1. Two complementary studies have been performed 
using budding yeast and several studies have been performed in mammalian cells. 
While studies in yeast utilized microarrays, more recent studies in mammalian cells 
have used RNAseq and NGS technology. The common genes that are induced have 
provided clues into which pathways are shared among eukaryotic organisms.
Keller-Seitz et al. [113] determined which budding yeast genes were induced after 
exposure to AFB1. Essentially, an exponentially grown culture was concentrated to 
4 × 10e8 cells/ml and then exposed to 25 μM AFB1 in phosphate buffer (pH 7.5). After  
RNA was extracted, cDNA was synthesized and labeled for analysis on microarrays. 
Fourteen DNA repair genes were upregulated more than two-fold, with RAD51 
being upregulated more than seven-fold. Among NER genes, RAD16, RAD3, and 
RAD1 were AFB1-inducible. The upregulation of selected genes was verified by 
RT-PCR. Additional genes that were induced included those involved in mismatch 
repair and DNA synthesis, while genes participating in NHEJ were downregulated.
A similar study was done by Guo et al. [136], except AFB1-inducible genes were 
identified in actively growing cultures. Similar to the Keller-Seitz study [113], 
RAD51 was upregulated over seven-fold. However, additional genes involved in 
Figure 4. 
DNA damage tolerance mechanisms used to bypass a AFB1-Fapy DNA adduct blocking the leading strand 
polymerase on a growing replication fork. Error-free (left) bypass uses a template switch mechanism while error-
prone (right) bypass uses a low fidelity DNA polymerase, resulting in the insertion of an A opposite the DNA adduct.
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regulating dNTP levels were also upregulated including DUN1, which encodes a 
DNA damage-signaling kinase, and RNR2 and RNR4, which are subunits of ribo-
nucleotide reductase. Although the functional significance of the AFB1-associated 
inducibility is unknown, there is good overlap with a cluster of genes identified as 
DNA damage-inducible but not generally stress-inducible [137]; DNA damage-
inducible genes from multiple studies include DUN1, RAD51, RNR2, and RNR4. In 
contrast to the previous study by Keller-Seitz, NER genes were not upregulated. In 
both studies, the DNA damage-inducibility of RAD51 is MEC1-dependent; MEC1 is 
the ATM/ATR orthologue of yeast. The functional significance of the upregulation 
was illustrated by showing that the recombination deficiency exhibited by mec1 
mutants could be partially suppressed by over-expression of RAD51 [113]. Thus, 
upregulation of particular DNA repair genes could enhance AFB1 genotoxic effects.
Additional genes that were upregulated in both studies included genes involved 
in cell cycle control, protein transport, DNA metabolism, and ion homeostasis 
[113, 136]. Although the functional significance of the upregulation of each of 
these genes is unknown, many of these genes are involved cell cycle regulation. 
Interestingly, genes involved in histone biosynthesis were downregulated, reflecting 
a delay in S phase [136]. The delay in S phase may result from the stability of the 
AFB1-Fapy DNA adduct during the exposure time.
Identification of AFB1-inducible genes in mammalian cells revealed broader 
classes of upregulated genes, compared to the yeast studies, reflecting the hepatic 
cell’s ability to metabolize and neutralize xenobiotic agents. Merrick et al. [138] 
performed RNA seq analysis on liver cells after the rat was injected with AFB1. In 
brief, RNA was obtained from male rats exposed 1 ppm AFB1 in feed for 90 days, and 
RNA seq analysis was performed using the appropriate number of unexposed rats as 
controls. 1026 differentially induced transcripts were identified. Genes upregulated 
more than five-fold relevant to hepatocellular proliferation include follistatin (442-
fold), Aldh3a1 (302-fold), Mybl2 (21-fold), Mybl1 (6-fold), and Sox9 (6-fold). Genes 
upregulated and involving the E2f1 transcription factor included Cdk1, Mdm2, Ect2, 
Mad2L1, and Nuf2. Of those genes that were upregulated, of particular interest are 
those involved in DNA damage tolerance and repair. A two to four-fold increase was 
observed for Mgmt, Top2a, Rad51, Rad18, Xrcc6, Mnd1, and Tynns [138]. These stud-
ies indicate that chronic AFB1 exposure in animals can also induce DNA repair genes 
that are involved in cell cycle regulation and DNA replication bypass.
2.13 Signal transduction and checkpoint activation
Both studies in yeast and in mammalian cells indicate that AFB1 triggers a check-
point response that delays cell cycle progression so that DNA damage can be repaired. 
The mechanism by which the AFB1 DNA adducts are sensed is unknown. However, it 
is likely that DNA replication stress triggers S phase delay that is associated with Rad53 
(Chk2 orthologue) phosphorylation [133]. In budding yeast, exposure to 50 μM AFB1 
is sufficient to delay S phase [133, 135]. The Rad53 phosphorylation is dependent on 
MEC1, the ATM/ATR orthologue. Fasullo et al. [133] observed that the downstream 
effector of Rad53, DUN1, was required for both AFB1-associated mutation and AFB1-
associated recombination. However, the substrates for the signaling cascade that affect 
AFB1-associated recombination and mutation are unknown. One possibility is that 
Rad55 phosphorylation is important in triggering AFB1-associated recombination.
In mammalian cells, the DNA damage response to AFB1-associated DNA adducts 
has been addressed by only a few studies. After exposure to AFB1, HepG2 cells exhibit 
53BP1 foci and H2AX foci but not Chk1 or Chk2 activation [139]. However, other stud-
ies [140] in other cell lines suggest a robust stimulation of the checkpoint response. 
In human bronchial epithelial cells (BEAS-2B) expressing CYP2A13 and exposed to 
DNA Repair - An Update
18
low concentrations of AFB1, AFB1-DNA adducts and 8oxodG significantly increased, 
along with phosphorylation of ATR and BRCA1. In addition, Mre11, Rad50 and Rad51 
were significantly increased. These studies suggest that similar to yeast, checkpoint 
activation leads to higher expression of DNA recombination genes in3BEAS-2B cells.
3. Conclusions
Liver cancer is the third leading cause of cancer deaths, and unfortunately the 
incidence of liver cancer is increasing in the USA. Environmental and lifestyle factors 
include AFB1 exposure and infection with HCV and HBV viruses. AFB1 is a potent liver 
carcinogen because it is a potent genotoxin and AFB1 exposure is correlated to signature 
mutations found in HCC. Liver injury and inflammation set the stage for regenerative 
cell proliferation that enhances AFB1-associated genetic instability. As liver cancer 
progresses, multiple genetic mutations and epigenetic changes accumulate that eventu-
ally accelerate an irreversible path toward malignancy and poor prognosis.
Nonetheless, cellular defense mechanisms have evolved to diminish the AFB1 geno-
toxicity and repair or tolerate AFB1 DNA adducts so that mutations and chromosomal 
instability are avoided. First, there are multiple pathways to repair AFB1-associated 
DNA adducts. These include BER repair involving NEIL1 and NER pathways that excise 
AFB1-associated DNA adducts. However, it is still unclear which pathway is favored 
in humans and whether they are redundant. Second, there are common repair and 
checkpoint pathways that are upregulated in both model organisms and in mammalian 
organisms; these include ATR signaling pathways and recombinational repair pathways. 
These pathways may suppress chromosomal instability by error-free mechanisms by 
which DNA adducts can be bypassed by the DNA replication machinery. One error 
free mechanism involves recombination-mediated template switch mechanisms. 
Supporting this idea, RAD51 expression is enhanced in yeast and particular polymor-
phisms XRCC3, a RAD51 paralogue, may be risk factors for HCC. Nonetheless the DNA 
repair process can be thwarted by HBV virus, where Hepatitis B virus may directly 
interfere with NER and perpetuate the replication of cells containing damaged DNA.
The studies presented in this chapter point to future directions in elucidating 
repair mechanisms of AFB1-associated DNA damage and genetic susceptibility to 
AFB1-associated cancer. The advent of NGS technology has made it possible to profile 
the yeast and mammalian genomes for AFB1 resistance which will facilitate identify-
ing the most prominent AFB1 resistant genes. This will facilitate epidemiological 
studies in determining potential gene polymorphisms that may pose the greatest risk 
for HCC. NGS technology can facilitate characterizing the DNA sequence contexts 
where AFB1-associated mutations occur. With the advent of NGS it may be possible 
to determine the temporal and sequence contexts by with AFB1-associated mutations 
occur. With the accumulation of genetic information, new biomarkers may be avail-
able to aid clinicians and epidemiologists to detect individuals most of risk for HCC 
and to take appropriate prophylactic actions at earl signs of HCC progression.
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